



Liver transplantation for cholangiocarcinoma: exploring a new land

Lin-Feng He^{1,2,3}, Tao Lv^{1,2}, Yong-Fa Huang^{4,5}, Yao Xiao⁶, Gang Xu^{1,2}, Jia-Yin Yang^{1,2}

¹Liver Transplant Center, Organ Transplant Center, West China Hospital of Sichuan University, Chengdu, China; ²Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, Chengdu, China; ³West China School of Medicine, Sichuan University, Chengdu, China; ⁴Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China; ⁵Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China; ⁶Division of Transplant Surgery, Department of Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Correspondence to: Dr. Gang Xu, MD. Liver Transplant Center, Organ Transplant Center, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital of Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu 610041, China. Email: gangxu@wchscu.cn; Prof. Jia-Yin Yang, MD, PhD. Liver Transplant Center, Organ Transplant Center, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu 610041, China. Email: doctoryjy@scu.edu.cn.

Comment on: Laughlin BS, Petersen MM, Yu NY, *et al.* Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. *J Gastrointest Oncol* 2022;13:288-97.

Submitted Jun 20, 2022. Accepted for publication Aug 11, 2022.

doi: 10.21037/jgo-22-596

View this article at: <https://dx.doi.org/10.21037/jgo-22-596>

Liver transplantation (LTx) for cholangiocarcinoma (CCA): exploring a new land

CCA is a rare malignancy arisen from biliary system, whose incidence is increasing in these years. According to the tumor anatomical location with the second-order bile ducts, CCA is classified as intrahepatic CCA (iCCA) and extrahepatic CCA (eCCA). Surgical resection is a preferred management of cholangiocarcinoma, when radiofrequency ablation, transarterial chemoembolisation, and radiotherapy are optional treatments for those unresectable tumors (1). LTx is a considerable treatment with some liver diseases, especially early-stage hepatocellular carcinoma and is widely performed over the world, providing better prognosis. However, CCA is considered as contraindication of LTx for a long time until some studies reveal the potential management in selected patients.

Recently, Laughlin *et al.* published a retrospective single-center study in the *Journal of Gastrointestinal Oncology* and reported the different outcomes for patients with eCCA undergoing three different regimens: neoadjuvant chemoradiotherapy (nCRT) and orthotopic LTx, surgical resection and adjuvant chemoradiotherapy (aCRT), and

definitive chemoradiotherapy (dCRT) (2). In their study, 20 out of 65 patients underwent orthotopic LTx after nCRT, 16 patients were treated with surgical resection and aCRT, and the rest 29 patients received dCRT only. The overall survival (OS) of patients at 3 and 5 years in nCRT group (78% and 59%) and aCRT group (49% and 38%) was significantly improved than that in dCRT group (16% and 0%), resulting from treatment strategy only in multivariate analysis. Also, the local progression-free survival and disease-free survival were higher in nCRT group (50% and 61%) and aCRT group (30% and 30%) than these in dCRT group (0% and 0%). Unlike poor outcomes reported in LTx treatment alone, undergoing nCRT before LTx improved the prognosis. In the era of neoadjuvant treatment for CCA combining LTx with chemoradiotherapy, this research provides a new potential approach to manage some featured patients with eCCA.

For CCA, the treatments are limited, especially for unresectable tumors, and risk of recurrence is high (3,4). So, good survivals of LTx treatment are encouraging. LTx for eCCA, especially perihilar CCA (pCCA), began long times ago but the outcomes were not so satisfactory until

Table 1 Recruiting prospective clinical trials of liver transplantation for cholangiocarcinoma

Type	Estimated participants	Stage	Combined therapy	Institution/country	Study start date	Estimated study completion date	Phase	ClinicalTrials.gov ID
iCCA	30	Very early	NA	University Health Network, Canada	April 2018	January 2029	Phase II	NCT02878473
iCCA	15	Unresectable	nCRT	Oslo University Hospital, Norway	June 2020	May 2035	NA	NCT04556214
pCCA	15	Unresectable	nCRT	Oslo University Hospital, Norway	September 2021	May 2045	NA	NCT04993131
pCCA	34	Unresectable	nCRT	Hospital Vall d'Hebron, Spain	April 2020	June 2025	NA	NCT04378023
CCA	100	Unresectable	nCRT	Washington University School of Medicine, USA	August 2005	December 2022	NA	NCT00301379

iCCA, intrahepatic cholangiocarcinoma; pCCA, perihilar cholangiocarcinoma; NA, not applicable; nCRT, neoadjuvant chemoradiotherapy.

the use of neoadjuvant chemoradiotherapy before LTx in Mayo protocol (5). In the protocol, patients should be with pathologically confirmed pCCA or evaluated carbohydrate antigen 19-9 (>100 ng/mL) with radiologically malignant stricture. Besides, the size of tumor should be under 3 cm without distant metastases and lymph node metastases. Appropriate patients will receive a consecutive therapy of external-beam irradiation with intravenous 5-fluorouracil (5-FU), brachytherapy and oral maintenance capecitabine when they are waiting for LTx. The 5-year OS of patient was up to 82%. A more recent multi-center retrospective research also reported similar result in strict selected patients with pCCA undergoing neoadjuvant regime of Mayo protocol (6). Patients undergoing LTx had better OS (3-year: 72%; 5-year: 54%) than that of resection (3-year: 44%; 5-year: 19%). Similarly, a meta-analysis involving 428 patients shows improved 5-year OS rates and less recurrence in neoadjuvant chemoradiation group (65.1%; 24.1%) compared to the LTx only (31.6%; 51.7%) (7).

Regime of neoadjuvant chemoradiation before LTx is also suitable for iCCA. Sapisochin *et al.* perform a retrospective multicenter study on neoadjuvant chemoradiation before LTx in very early iCCA, defined as single tumors ≤ 2 cm. The 5-year OS is better in very early iCCA group (65%) than that in advanced iCCA group (45%). Meanwhile, the 5-year cumulative risk of recurrence in very early iCCA group (18%) is lower than that in advanced iCCA group (61%). Interestingly, McMillan *et al.* provided good outcomes for patients with locally-advanced, unresectable iCCA receiving LTx after neoadjuvant therapy (8). The

locally-advanced, unresectable iCCA is defined as a single tumor ≥ 2 cm or multiple tumors without distant metastases, lymph node metastases and encasement or involvement of major vascular structures. Patients received neoadjuvant therapy for 6 months and disease should be stable without extrahepatic disease before LTx was performed. The OS at 1-, 3-, and 5-year is 100%, 71%, and 57%, which supported LTx with neoadjuvant therapy as an effective regime for locally-advanced, unresectable iCCA.

In summary, some highly-selected patients with CCA may be the potential candidate for LTx along with neoadjuvant chemoradiation. Remarkably, the roles of LTx as a reasonable therapeutic strategy for CCA is being extensively studied (*Table 1*) and we await the outcomes of large-scale randomized prospective studies. Additionally, targeted therapy and immunotherapy are widely applied to the treatment of cholangiocarcinoma as more and more molecular therapeutic targets of are revealed (9,10). Combining targeted therapy and immunotherapy with neoadjuvant therapy before LTx may lead to a more satisfying prognosis.

Acknowledgments

Funding: This study was supported by the National Natural Science Foundation of China (No. 82070674), the Natural Science Foundation of Sichuan Province (No. 2022NSFSC0843), the Sichuan Science and Technology Program (No. 2019YFG0036), the China Postdoctoral Science Foundation (No. 2022M712262).

Footnote

Provenance and Peer Review: This article was a standard submission to the journal. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jgo.amegroups.com/article/view/10.21037/jgo-22-596/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Zhang W, Song T. Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives. *Hepatobiliary Surg Nutr* 2021;10:878-80.
2. Laughlin BS, Petersen MM, Yu NY, et al. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. *J Gastrointest Oncol* 2022;13:288-97.
3. Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. *Nat Rev Dis Primers* 2021;7:65.
4. Qu WF, Liu WR, Shi YH. Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus. *Hepatobiliary Surg Nutr* 2021;10:887-9.
5. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. *Semin Liver Dis* 2004;24:201-7.
6. Ethun CG, Lopez-Aguilar AG, Anderson DJ, et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. *Ann Surg* 2018;267:797-805.
7. Cambridge WA, Fairfield C, Powell JJ, et al. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma. *Ann Surg* 2021;273:240-50.
8. McMillan RR, Javle M, Kodali S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. *Am J Transplant* 2022;22:823-32.
9. Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. *Ann Oncol* 2021;32:1111-26.
10. Eso Y, Seno H. Optimization of immunotherapy for patients with hepatobiliary cancer. *Hepatobiliary Surg Nutr* 2021;10:717-9.

Cite this article as: He LF, Lv T, Huang YF, Xiao Y, Xu G, Yang JY. Liver transplantation for cholangiocarcinoma: exploring a new land. *J Gastrointest Oncol* 2022;13(5):2696-2698. doi: 10.21037/jgo-22-596